JSC “Grindeks” informs that it has received approval from the
government agency “Investment and Development Agency of Latvia” of
allocation of the co-financing from the European Regional
Development Fund for the construction of UDCA (ursodeoxycholic
acid) manufacturing unit. Allocated amount of co-financing is 2.8
million lats.
About JSC “Grindeks”
“Grindeks” is the leading pharmaceutical company in the Baltic
States. The main directions of its operation are research,
development, manufacturing and sales of original products, as well
as generics and active pharmaceutical ingredients. “Grindeks”
specializes in the heart and cardiovascular, psychotropic and
anti-cancer therapeutic groups of medications.
“Grindeks” concern consists of four subsidiary companies in Latvia,
Estonia and Russia; as well as representatives and representative
offices in 14 countries. Products of the company are exported to
more than 40 countries and its export comprises more than 96% of
the total turnover. The main markets are the Baltic States, Russia
and other CIS countries, as well as Japan and USA. The shares of
JSC „Grindeks” are listed in the Official List of “NASDAQ OMX
Riga”.
Further information:
Laila Kļaviņa
Head of the Communications Department
JSC “Grindeks”
E-mail: laila.klavina@grindeks.lv
Phones: +371 67083370, +371 29256012
|